8-K: enGene Announces Q2 2024 Financial Results and Expands EG-70 Clinical Development

enGene Holdings Inc. reported its second quarter 2024 financial results and announced an expansion of its EG-70 clinical program into high-risk papillary-only non-muscle invasive bladder cancer.

Summary

• enGene Holdings Inc. announced its financial results for the second quarter ended April 30, 2024, and provided a business update.
• The company plans to expand its LEGEND study to include a cohort focused on patients with high-risk, BCG-unresponsive papillary-only NMIBC.
• Interim data for the LEGEND BCG-unresponsive cohort is expected by the end of September 2024.
• The company anticipates filing a Biologics License Application (BLA) for EG-70 in mid-2026.
• enGene has paused pre-clinical development of EG-i08 for cystic fibrosis to prioritize bladder cancer programs.
• Cash and cash equivalents were $264.8 million as of April 30, 2024, which is expected to fund operations into 2027.
• Total operating expenses for the quarter were $17.3 million, compared to $4.7 million in the same period last year.
• The net loss attributable to common shareholders was approximately $15.0 million, or $0.38 per share, compared to $6.5 million, or $9.30 per share, for the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong clinical data and a clear path forward for EG-70, but also acknowledges increased expenses and a net loss. The expansion of the clinical program and the anticipated BLA filing are positive signals.

Positives

• The company has a strong cash position of $264.8 million, expected to fund operations into 2027.
• EG-70 has a favorable safety profile with no safety-related patient discontinuations in the Phase 1 study.
• The EG-70 program is designed for ease of use in any urology clinic, with no special handling requirements.
• The non-viral DDX platform supports low cost of goods and scalable manufacturing.
• The company has a strong intellectual property portfolio with protection through at least 2040.

Negatives

• The company's net loss increased to $15.0 million for the quarter, compared to $6.5 million in the same period last year.
• Research and development expenses increased significantly due to manufacturing and clinical costs related to the EG-70 study.
• General and administrative expenses also increased due to headcount costs and professional fees.
• The company has deprioritized the pre-clinical development of EG-i08 for cystic fibrosis.

Risks

• The company's ability to secure regulatory approval for EG-70 on anticipated timelines is subject to risks and uncertainties.
• Clinical trial results may differ materially from expectations.
• The company's ability to recruit and retain qualified personnel is a risk.
• There are risks associated with establishing clinical trial sites and enrolling patients.
• The company's financial results may be impacted by various factors, including market conditions and competition.

Future Outlook

The company expects its existing cash and cash equivalents will fund operating expenses, debt obligations, and capital expenditures into 2027. enGene plans to expand the clinical development of EG-70 within the bladder and anticipates filing a BLA for EG-70 in mid-2026.

Management Comments

• Jason Hanson, Chief Executive Officer of enGene, stated that the $200 million private placement in February positioned the company well to develop EG-70 across multiple bladder cancer indications.
• Jason Hanson also mentioned that the planned initial expansion of the LEGEND study will include a cohort focused on enrollment of patients with high-risk, BCG-unresponsive papillary-only NMIBC.
• Management believes the design of EG-70 positions it well to seamlessly slot into the standard of care.

Industry Context

This announcement is significant as it highlights enGene's focus on addressing the unmet needs in bladder cancer treatment, particularly in the BCG-unresponsive NMIBC space. The company's non-viral approach and ease-of-use design for EG-70 could provide a competitive advantage in the market.

Comparison to Industry Standards

• The company's EG-70 program is compared to other bladder cancer treatments such as cretostimogene and Adstiladrin.
• EG-70 is designed to be easier to administer than other treatments, with no special handling requirements, unlike Adstiladrin which requires a 3-10 hour vial thaw and universal biosafety precautions.
• EG-70 has a 73% complete response rate at any time in the Phase 1 LEGEND study, which is comparable to the 62% CR rate at 3 months for cretostimogene and 65% CR rate at 6 months for Adstiladrin.
• The company's non-viral approach is a key differentiator from viral-based therapies like Adstiladrin and cretostimogene.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the EG-70 clinical program.
• Employees may be impacted by the company's growth and strategic changes.
• Patients with bladder cancer stand to benefit from the development of EG-70.
• Urologists will be impacted by the potential introduction of a new treatment option for bladder cancer.

Next Steps

• The company will release interim data from the LEGEND study's BCG-unresponsive cohort by the end of September 2024.
• Enrollment for the papillary-only LEGEND expansion cohort is expected to begin in the fourth quarter of 2024.
• The company plans to file a Biologics License Application (BLA) for EG-70 in mid-2026.

Key Dates

Keywords

EG-70, bladder cancer, NMIBC, genetic medicines, clinical trial, Biologics License Application, BCG-unresponsive, papillary-only, DDX platform, urology